Search results for " KUBio" in Articles / App Notes
Article
A Second Modular Biopharma Facility Opens: KUBio in Hangzhou
To bring advanced biosimilar products to the Chinese market quickly, Pfizer’s Global Biotechnology Center will make use of Cytiva’s KUBio advanced modular manufacturing solution. KUBio modules …
Article
KUBio modular biopharm facility built in Germany, assembled in China
Cytiva is supplying a full biopharmaceutical processing solution, known as a KUBio, to JHL Biotech in Wuhan, China. The sixty-two completed modules that make up the factory have completed the journe…
Article
Cytiva to Expand KUBio Through Close Collaboration with Pharmadule Morimatsu
Cytiva has announced it will be working closely with Pharmadule Morimatsu to expand its KUBio “factory in a box” so that biopharma manufacturers will be able to quickly scale up vaccines, viral vect…
Article
Flexible Facilities for Viral Vector Manufacturing
Cytiva has amassed expertise in modular design and construction with the use of its FlexFactory (a modular end-to-end biomanufacturing platform) as well as its KUBio facility (the FlexFactory inside o…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
According to Cytiva, the cost of a KUBio plant can be as much as 45% lower than a comparable, traditional facility
This year, Process Development Forum will continue to report on drug approvals, i…
Article
Gene Therapies Push Viral Vector Production
At Cytiva, the company offers a structural solution to increasing viral vector manufacturing capacity through its KUBio box, a modular biomanufacturing environment. The company has tailored its KUBio …
Article
A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
The facility, the first built using the KUBio system (Cytiva), was completed in 18 months. Parrish Galliher, chief technology officer, upstream, Cytiva, provided an overview of the KUBio facility and …
Article
The Good and Bad of Biosimilars
Biosimilars have been around for years, but the biopharma industry – as well as the healthcare community – has been slow to embrace them. Today, however, the competition is really beginning to heat …
Article
Biopharma Says It Has an Evolution in New Technologies and Processes
Cytiva introduced prefabricated, modular KUBio manufacturing units for the production of viral vector-based therapeutics including viral-vector based vaccines, oncolytic viruses, and gene and cell the…
Article
Going Viral
The new KUBio BSL-2 solution for viral vector-based therapeutics, including oncolytic vaccines and cell and gene therapies allows manufacturers to quickly build a ready-to-run, prefabricated modular m…